SCHEMBL15907134

SCHEMBL15907134

CC(C)(C)c1nnc2cc(C(N)=O)cnn12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
LTK P29376 1/20 0.35
CSNK1A1 P48729 1/20 0.35
CDK8 P49336 1/20 0.35
CLK2 P49760 1/20 0.35
CDK5 Q00535 1/20 0.35
ACVR1 Q04771 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MKNK1 Q9BUB5 4/20 0.34
MKNK2 Q9HBH9 4/20 0.34
LMNA P02545 2/20 0.34
EGLN2 Q96KS0 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
NFKB1 P19838 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907137 0.88 HCAR2 (0.35) LMNAEGLN2KDM4EALDH1A1CYP1A2
SCHEMBL15907136 0.84 ATM (0.40) LMNAEGLN2KDM4EALDH1A1HPGD
SCHEMBL18323598 0.79 KDM4E (0.47) MKNK1MKNK2LMNAEGLN2KDM4E
SCHEMBL18323670 0.75 MKNK1 (0.34) MKNK1MKNK2LMNAEGLN2KMT2A
SCHEMBL15907124 0.74 MEN1 (0.36) AURKACSF1RRETLTKCSNK1A1
SCHEMBL15907118 0.74 MAPK13 (0.46) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL15907138 0.73 MAPK14 (0.36) LMNAKDM4EALDH1A1CYP1A2HPGD
SCHEMBL15907122 0.73 MEN1 (0.49) AURKACSF1RRETLTKCSNK1A1
SCHEMBL15907092 0.71 MEN1 (0.34) MEN1KMT2A
SCHEMBL15907103 0.71 MEN1 (0.34) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 AURKA 212/4885CSF1R 1848/4885RET 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.